Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Anthracycline analogs: the past, present, and future.

× No keyword cloud information.

89 in total

1. Relationship between effects on nucleic acid synthesis in cell cultures and cytotoxicity of 4-demethoxy derivatives of daunorubicin and adriamycin.

Authors: R Supino; A Necco; T Dasdia; A M Casazza; A Di Marco
Journal: Cancer Res Date: 1977-12 Impact factor: 12.701

2. Phase II study of 4-demethoxydaunorubicin in advanced ovarian carcinoma.

Authors: T B Hakes; A N Daghestani; J B Dougherty; L Weiselberg; V Raymond
Journal: Cancer Treat Rep Date: 1985-05

3. Adriamycin (NSC-123,127): a new antibiotic with antitumor activity.

Authors: A Di Marco; M Gaetani; B Scarpinato
Journal: Cancer Chemother Rep Date: 1969-02

4. Phase I and clinical pharmacological evaluation of 4'-deoxydoxorubicin in patients with advanced cancer.

Authors: G F Stanton; V Raymond; R E Wittes; P Schulman; D Budman; R Baratz; L Williams; G R Petroni; N L Geller; C Hancock
Journal: Cancer Res Date: 1985-04 Impact factor: 12.701

5. Activity and distribution of iv and oral 4-demethoxydaunorubicin in murine experimental tumors.

Authors: M Broggini; C Italia; T Colombo; L Marmonti; M G Donelli
Journal: Cancer Treat Rep Date: 1984-05

6. Fluorescence assays and pharmacokinetic studies of 4'-deoxydoxorubicin and doxorubicin in organs of mice bearing solid tumors.

Authors: F Formelli; C Pollini; A M Casazza; A di Marco; A Mariani
Journal: Cancer Chemother Pharmacol Date: 1981 Impact factor: 3.333

7. Electrocardiographic and transmembrane potential effects of 5-iminodaunorubicin in the rat.

Authors: R A Jensen; E M Acton; J H Peters
Journal: Cancer Res Date: 1984-09 Impact factor: 12.701

8. Phase II trial of 4'-epi-doxorubicin in metastatic colorectal carcinoma.

Authors: J A Wils
Journal: Invest New Drugs Date: 1984 Impact factor: 3.850

9. Phase I study of 4-demethoxydaunorubicin.

Authors: V Bonfante; L Ferrari; F Villani; G Bonadonna
Journal: Invest New Drugs Date: 1983 Impact factor: 3.850

Review 10. The effectiveness of the anthracycline analog 4'-epidoxorubicin in the treatment of experimental tumors: a review.

Authors: A Goldin; J M Venditti; R Geran
Journal: Invest New Drugs Date: 1985 Impact factor: 3.850

43 in total

1. Differences in lipoprotein concentration and composition modify the plasma distribution of free and liposomal annamycin.

Authors: K M Wasan; R E Morton
Journal: Pharm Res Date: 1996-03 Impact factor: 4.200

10. Reduced cardiotoxicity of doxorubicin given in the form of N-(2-hydroxypropyl)methacrylamide conjugates: and experimental study in the rat.

Authors: T K Yeung; J W Hopewell; R H Simmonds; L W Seymour; R Duncan; O Bellini; M Grandi; F Spreafico; J Strohalm; K Ulbrich
Journal: Cancer Chemother Pharmacol Date: 1991 Impact factor: 3.333

Anthracycline analogs: the past, present, and future.

1. Relationship between effects on nucleic acid synthesis in cell cultures and cytotoxicity of 4-demethoxy derivatives of daunorubicin and adriamycin.

2. Phase II study of 4-demethoxydaunorubicin in advanced ovarian carcinoma.

3. Adriamycin (NSC-123,127): a new antibiotic with antitumor activity.

4. Phase I and clinical pharmacological evaluation of 4'-deoxydoxorubicin in patients with advanced cancer.

5. Activity and distribution of iv and oral 4-demethoxydaunorubicin in murine experimental tumors.

6. Fluorescence assays and pharmacokinetic studies of 4'-deoxydoxorubicin and doxorubicin in organs of mice bearing solid tumors.

7. Electrocardiographic and transmembrane potential effects of 5-iminodaunorubicin in the rat.

8. Phase II trial of 4'-epi-doxorubicin in metastatic colorectal carcinoma.

9. Phase I study of 4-demethoxydaunorubicin.

Review 10. The effectiveness of the anthracycline analog 4'-epidoxorubicin in the treatment of experimental tumors: a review.

1. Differences in lipoprotein concentration and composition modify the plasma distribution of free and liposomal annamycin.

2. Trastuzumab-induced cardiac dysfunction: A 'dual-hit'.

3. Pharmacokinetics and metabolism of iodo-doxorubicin and doxorubicin in humans.

Review 4. Antineoplastic drugs in 1990. A review (Part II).

5. Neurotoxicity and dermatotoxicity of cyanomorpholinyl adriamycin.

6. The protective activity of ICRF-187 against doxorubicin-induced cardiotoxicity in the rat.

Review 7. Streptomycetes producing daunomycin and related compounds: do we know enough about them after 25 years?

8. Topical dimethylsulfoxide may prevent tissue damage from anthracycline extravasation.

9. Doxorubicin-heparin complex: reduction of cardiotoxicity of doxorubicin.

10. Reduced cardiotoxicity of doxorubicin given in the form of N-(2-hydroxypropyl)methacrylamide conjugates: and experimental study in the rat.